NEW YORK, Feb. 26 – Xerion Pharmaceuticals has acquired exclusive rights to cancer targets identified by a Tufts University scientist, the company said today.

The Martinsried, Germany-based firm, in a statement, said it will use the targets to create therapeutic antibodies. The targets were identified in the lab of Daniel Jay, a professor of physiology at Tufts.

Financial details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.